| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 05/30/2002 | WO2002042484A2 Method for producing pectin hydrolysis products |
| 05/30/2002 | WO2002042465A1 Production of stilbenes in transgenic plants and the method of producing thereof |
| 05/30/2002 | WO2002042456A2 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof |
| 05/30/2002 | WO2002042445A2 Differentiated cells suitable for human therapy |
| 05/30/2002 | WO2002042443A2 Use of modulators of eukaryotic signal transduction pathways for the treatment of helicobacter infections |
| 05/30/2002 | WO2002042436A2 Isolated human phosphatase proteins, nucleic acid molecules encoding them, and uses thereof |
| 05/30/2002 | WO2002042433A1 Method of amplifying natural killer cells shifting into th2 or th1 type |
| 05/30/2002 | WO2002042432A2 Epothilone resistant cell lines |
| 05/30/2002 | WO2002042429A2 Methods of isolating amyloid-inhibiting compounds and use of compounds isolated from uncaria tomentosa and related plants |
| 05/30/2002 | WO2002042335A1 Polysaccharide compound having immune stimulating activity |
| 05/30/2002 | WO2002042332A2 Truncated cd200 |
| 05/30/2002 | WO2002042330A2 Cystoskeleton-associated proteins |
| 05/30/2002 | WO2002042325A2 Cyp1b1 nucleic acids and methods of use |
| 05/30/2002 | WO2002042321A2 Mixed fibrils |
| 05/30/2002 | WO2002042319A2 2-substituted estrogens as antiangiogenic agents |
| 05/30/2002 | WO2002042318A2 Transcobalamin receptor binding conjugates for neutron capture therapy |
| 05/30/2002 | WO2002042316A2 Pna analogues |
| 05/30/2002 | WO2002042306A1 Benzimidazole derivatives, preparation and therapeutic use thereof |
| 05/30/2002 | WO2002042303A2 Acyl and sulfonyl derivatives of 6,9-disubstituted 2-(trans-1,4-diaminocyclohexyl)-purines and their use as antiproliferative agents |
| 05/30/2002 | WO2002042298A1 Aminothiazoles and their use as adenosine receptor antagonists |
| 05/30/2002 | WO2002042296A1 Farnesyl transferase inhibiting benzoheterocyclic derivatives |
| 05/30/2002 | WO2002042295A2 Peptides as met-ap2 inhibitors |
| 05/30/2002 | WO2002042280A2 Pyrimidine derivatives |
| 05/30/2002 | WO2002042278A2 Imidazole and benzimidazole caspase inhibitors and uses thereof |
| 05/30/2002 | WO2002042276A1 Quarternary proforms of tertiary amine containing compounds |
| 05/30/2002 | WO2002042273A2 Acid derivatives useful as serine protease inhibitors |
| 05/30/2002 | WO2002042272A2 Substituted polycyclic aryl and heteroaryl pyridines useful for selective inhibition of the coagulation cascade |
| 05/30/2002 | WO2002042269A1 3-arylindole derivatives and their use as cb2 receptor agonists |
| 05/30/2002 | WO2002042265A2 Cyanoguanidine prodrugs |
| 05/30/2002 | WO2002042257A1 Substituted cyclohexane derivates and the use thereof in medicaments for treating cardiovascular diseases |
| 05/30/2002 | WO2002042247A1 Retiferol derivatives and their use in the treatment of skin diseases or conditions associated with photodamage |
| 05/30/2002 | WO2002041923A1 Preparation for curing oncological disease, method for producing and using said composition |
| 05/30/2002 | WO2002041912A1 Drugs and foods improving the quality of life and process for producing the same |
| 05/30/2002 | WO2002041908A1 Process for preparing aqueous extracts of plants and extracts so obtained |
| 05/30/2002 | WO2002041903A1 The composition of multipurpose high functional alkaline solution composition, preparation thereof, and for the use of nonspecific immunostimulator |
| 05/30/2002 | WO2002041896A2 Use of thienopyrimidines |
| 05/30/2002 | WO2002041882A2 Combination comprising an agent decreasing vegf activity and an agent decreasing egf activity |
| 05/30/2002 | WO2002041880A2 Use of pyrazolo[4,3-d]pyrimidines |
| 05/30/2002 | WO2002041844A2 Chemotherapeutic composition using nanocrystalline calcium phosphate paste |
| 05/30/2002 | WO2002041843A2 Antiinflammation agents |
| 05/30/2002 | WO2002041835A2 Estrogen receptor modulators |
| 05/30/2002 | WO2002028440B1 Methods and compositions for modulating t cell activation and uses thereof |
| 05/30/2002 | WO2002022648A3 Compositions and methods for inducing specific cytolytic t cell responses |
| 05/30/2002 | WO2002022599A3 Chemokine receptor binding heterocyclic compounds |
| 05/30/2002 | WO2002020736A9 Proteases |
| 05/30/2002 | WO2002020526A3 Cyclic and acyclic amidines and pharmaceutical compositions containing them for use as progesterone receptor binding agents |
| 05/30/2002 | WO2002018581A9 G-protein coupled receptors |
| 05/30/2002 | WO2002018438A9 Modified proteins, isolated novel peptides, and uses thereof |
| 05/30/2002 | WO2002005792A3 Use of matrix metalloprotease inhibitors for the treatment of cancer |
| 05/30/2002 | WO2002000663A3 Polycyclic xanthones as antibiotics |
| 05/30/2002 | WO2002000611A3 Fmoc-l-leucine and derivatives thereof as ppar-gamma agonists |
| 05/30/2002 | WO2001098270A3 N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
| 05/30/2002 | WO2001095928A3 Methods for regulating a cell-mediated immune response by blocking lymphocytic signals and by blocking lfa-1 mediated adhesion |
| 05/30/2002 | WO2001092565A8 Diagnosis of diseases associated dna transcription by means of assessing the methylation status of genes associated with dna transcription |
| 05/30/2002 | WO2001092333A3 Use of adnf for enhancing learning and memory |
| 05/30/2002 | WO2001091789A3 Combination of a mutant herpes virus and a chemotherapeutic agent for the treatment of cancer |
| 05/30/2002 | WO2001087979A3 Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci |
| 05/30/2002 | WO2001087934A3 Treatment of neoplasia/transformation using a pituitary tumor transforming gene carboxy terminal peptides |
| 05/30/2002 | WO2001085709A3 New compounds having anticancer activity: process for their preparation and pharmaceutical compositions containing them |
| 05/30/2002 | WO2001085686A3 Multicyclic compounds and the use as inhibitors of parp, vegfr2 and mlk3 enzymes |
| 05/30/2002 | WO2001078700A3 Compositions for use in modulating immune system function comprising at least one retrinoid and at least one cytokine |
| 05/30/2002 | WO2001077055A3 Specific salt forms of triphenylethylene derivatives as selective estrogen receptor modulators |
| 05/30/2002 | WO2001074780A8 Chemical complex comprising a pyridine carboxy derivative and an h2 histamine receptor antagonist |
| 05/30/2002 | WO2001068888A3 Production of chimeric capsid vectors |
| 05/30/2002 | WO2001068704A3 G-protein coupled receptors |
| 05/30/2002 | WO2001068679A3 Peptides targeting specifically tumor-derived endothelial cells |
| 05/30/2002 | WO2001066746A3 G-protein coupled receptor related polypeptides |
| 05/30/2002 | WO2001060343A3 Use of 2-methyl-thiazolidin-2,4-dicarboxylic acid and/or physiologically compatible salts thereof for producing a medicament for treating cancers |
| 05/30/2002 | WO2001051043A3 Compositions and methods for treatment of neoplastic diseases with combinations of limonoids, flavonoids and tocotrienols |
| 05/30/2002 | WO2001048187A3 A molecular switch for regulating mammalian gene expression |
| 05/30/2002 | WO2001046243A3 A new polypeptide-ring finger protein 8 and the polynucleotide encoding it |
| 05/30/2002 | WO2001041741A9 Hla class i a2 tumor associated antigen peptides and vaccine compositions |
| 05/30/2002 | WO2001016300A3 Method of identifying inhibitors of cdc25 |
| 05/30/2002 | WO2000078952A8 Human rna metabolism proteins (rmep) |
| 05/30/2002 | WO2000066581A8 Cyanopyrroles as progesterone receptor agonists |
| 05/30/2002 | WO2000052205A8 cDNA FOR HUMAN METHYLENETETRAHYDROFOLATE REDUCTASE |
| 05/30/2002 | US20020065416 Anti-inflammatory agents |
| 05/30/2002 | US20020065398 Humanized and chimeric monoclonal antibodies that recognize epidermal growth factor receptor (egf-r); diagnostic and therapeutic use |
| 05/30/2002 | US20020065397 Protecting therapeutic compositions from host-mediated inactivation |
| 05/30/2002 | US20020065391 Compound for use in the treatment of arthritis, inflammatory bowel disease, nervous system and cardiovascular disorders, arteriosclerosis, restenoses, diabetes, grafted organ damage, asthma, allergies, tumor metastasis and malaria |
| 05/30/2002 | US20020065327 Pharmaceutically active compounds and methods of use thereof |
| 05/30/2002 | US20020065315 For therapy and prophylaxis of asthma, cystic fibrosis, chronic obstructive pulmonary disease and rhinorrhea, convulsions, vascular spasms, coronary artery spasms, renal disorders, polycystic kidney disease, bladder spasms, etc. |
| 05/30/2002 | US20020065310 Method for treatment of tumors using nordihydroguaiaretic acid derivatives |
| 05/30/2002 | US20020065305 As antitumor agent |
| 05/30/2002 | US20020065304 As antitumor agent |
| 05/30/2002 | US20020065302 Cyclic AMP-specific phosphodiesterase inhibitors |
| 05/30/2002 | US20020065296 Administering heteroarylurea compound for therapy of cytokine mediated diseases and proteolytic enzyme mediated diseases |
| 05/30/2002 | US20020065292 Pyrazole compounds, pharmaceutical compositions, and methods for modulating or inhibiting ERAB or HADH2 activity |
| 05/30/2002 | US20020065282 Tetralone derivatives |
| 05/30/2002 | US20020065269 3-Sulfonylamino-c5 to c8-methyleneimino-2-carboxylic acid compound is effective for prophylaxis and treatment of inflammation, tissue degradation, cancer, fibrosis and related diseases |
| 05/30/2002 | US20020065264 Heterocylic leaving group containing -o-Het, or -s-Het, wherein Heterocyclic rings selected from pyridine, pyrole, furan, pyrimidine or proline derivatives |
| 05/30/2002 | US20020065257 17beta-amino and hydroxylamino-11beta-arylsteroids and their derivatives having agonist or antagonist hormonal properties |
| 05/30/2002 | US20020065241 A recombinant polynucleotide of first polynucleotides coding an antigenic peptide and are operatively linked to each other to enhance translation of the polynucleotides to the peptides and binding to MHC; cancer vaccine |
| 05/30/2002 | US20020065220 For use in diagnosis and therapy of disorders treating disorders related to these novel human immunoglobulin-like (Ig- like) proteins |
| 05/30/2002 | US20020065213 Increasing the duration of expression of a delivered gene in target cells by delivering a gene encoding a cellular retention activity and nuclear binding sequence to target cells before or during gene of interest delivery |
| 05/30/2002 | US20020064862 Preventing viral replication in cells; obtain cells, incubate with viricide, monitor cells for reduced viral activity |
| 05/30/2002 | US20020064856 Novel proteases |
| 05/30/2002 | US20020064848 Novel histidinol dehydrogenase |
| 05/30/2002 | US20020064843 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 05/30/2002 | US20020064826 Cytokine receptor-like polynucleotides, polypeptides, and antibodies |